OCTOBER 2018 Research Alert

This month we added five new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies explore three important areas within pharma: Real World Evidence (RWE) Generation, Digital Patient Engagement Programs and Outcomes-Based Contracting. Two of the new studies revolve around RWE in pharma - one examines the current and future utilization of extension studies while the other RWE document looks at the use of intervention studies. Addressing a different topical area are two studies that examine pharma's growing use of digital patient engagement programs. One of the studies presents staffing and spend benchmarks while the other study tackles performance metrics; both look at these issues in global, emerging and developed markets. The last study examines outcomes-based contract initiatives in pharma.

The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.

	Download: Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Staffing, Investment and Vendor Utilization for Digital Engagement (5523) Best Practices, LLC undertook this research to identify current staffing and spending levels for digital patient engagement programs. The study also examines vendor utilization and legal/compliance involvement for digital patient engagement.
	Download: Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Service Levels, Performance Metrics and Lessons Learned (5524) This study presents digital patient engagement benchmarks around drivers of program creation; depth and scope of engagement; and performance metrics.
	Download: Understanding the Changing Landscape of Real World Evidence Generation: Extension Studies (5527) Best Practices, LLC conducted this study to gain insights into current and future utilization of two RWE study methods (Concurrent Outcomes Studies and Extension Studies). The study also presents insights on the data collection methods used, the level of outsourcing used and valued vendor traits for these two study types.
	Download: Understanding the Changing Landscape of Real World Evidence Generation: Intervention Studies (5528) Intervention Studies, which in this research encompass three RWE study methods, are sometimes utilized by pharma companies. This study delivers insights into current and future utilization of three RWE study methods (Expanded Access Programs, Randomized Pragmatic Trials, and Other Low-Intervention Clinical Trials (not including Randomized Pragmatic Trials).
	Download: Outcomes-Based Contract Initiatives: Disrupting the High Cost of Prescription Medicines (5529) This research project provides a current picture of where the pharma industry is with outcomes-based contract initiatives; how well the agreements have met goals; what are timelines for creating agreements and the challenges companies have faced in developing agreements.